Ceera Investments LLC Grows Position in Pfizer Inc. (NYSE:PFE)

Ceera Investments LLC boosted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 24.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 56,502 shares of the biopharmaceutical company's stock after buying an additional 11,105 shares during the quarter. Ceera Investments LLC's holdings in Pfizer were worth $1,432,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Rialto Wealth Management LLC bought a new stake in Pfizer in the 4th quarter worth about $26,000. Clarity Asset Management Inc. bought a new position in shares of Pfizer in the fourth quarter valued at approximately $27,000. Gould Capital LLC increased its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares during the last quarter. North Capital Inc. bought a new stake in Pfizer during the first quarter worth $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in Pfizer in the fourth quarter worth $30,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. BMO Capital Markets decreased their price objective on shares of Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. Leerink Partners dropped their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research note on Wednesday, April 30th. Citigroup raised their price target on shares of Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Finally, HSBC dropped their price target on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $28.55.

Pfizer Trading Up 1.5%

Shares of PFE traded up $0.37 during midday trading on Tuesday, hitting $25.61. The stock had a trading volume of 50,917,197 shares, compared to its average volume of 41,733,598. The firm has a market cap of $145.60 billion, a PE ratio of 18.56, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58. The stock's 50 day moving average is $23.76 and its 200 day moving average is $24.81. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the prior year, the company earned $0.82 EPS. The business's revenue was down 7.8% compared to the same quarter last year. As a group, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.72%. Pfizer's dividend payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.